Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 2/2015

01-02-2015 | Original Article

Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial

Authors: D. V. Patel, M. Bolland, Z. Nisa, F. Al-Abuwsi, M. Singh, A. Horne, I. R. Reid, C. N. J. McGhee

Published in: Osteoporosis International | Issue 2/2015

Login to get access

Abstract

Summary

This prospective study showed that the incidence of acute anterior uveitis, confirmed by ophthalmic examination, in patients receiving intravenous zoledronate infusions as part of a randomized controlled trial for fracture prevention is 1.1 %.

Introduction

We prospectively investigated the incidence of ocular side effects after a single intravenous zoledronate infusion.

Methods

In a secondary analysis of a double-blind, placebo-controlled trial in which early post-menopausal women (N = 1054) with normal bone density or osteopenia were randomized to infusion of zoledronate 5 mg (N = 703) or placebo (N = 351), we analyzed significant adverse ocular events occurring within 3 months.

Results

Fourteen participants reported ocular symptoms after the infusion. All were examined by an ophthalmologist and eight were diagnosed with acute anterior uveitis (AAU) and one with sectoral episcleritis. The incidence of AAU and episcleritis was 1.1 % (95 % CI 0.5–2.1) and 0.1 % (95 % CI 0.0–0.7), respectively, in the zoledronate group and 0 % for both conditions in the placebo group (95 % CI 0.0–0.8). The mean time from infusion to symptom onset for AAU was 3 days (range 2–4). Three cases were bilateral. AAU was mild-moderate in seven participants and severe in one. All affected eyes were treated with topical cyclopentolate 1 % (to break, or minimize, posterior synechiae), and intensive, potent, topical corticosteroids with a tapering regime based on treatment response. The mean duration of topical corticosteroid was 26 ± 10 days (range 17–44). The mean, best corrected visual acuity was 20/20 (range 20/20–20/40) at presentation, which remained unchanged after AAU resolution. None of the participants lost vision, and no long-term sequelae were reported at last follow-up (range 3–13 months post-infusion).

Conclusions

Prescribers should inform patients about the possibility of ocular side effects with zoledronate infusions and refer promptly to an ophthalmologist if symptoms develop.
Literature
1.
Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–22PubMedCrossRef
2.
Hosking D, Lyles K, Brown JP et al (2007) Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 22:142–8PubMedCrossRef
3.
Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–809PubMedCrossRef
4.
Reid IR, Gamble GD, Mesenbrink P et al (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380–7PubMedCrossRef
5.
Sauty A, Pecherstorfer M, Zimmer-Roth I et al (1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133–9PubMedCrossRef
6.
Kunzmann V, Bauer E, Wilhelm M (1999) Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340:737–8PubMedCrossRef
7.
Durnian JM, Olujohungbe A, Kyle G (2005) Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye 19:221–2PubMedCrossRef
8.
Woo TCS, Joseph DJ, Wilkinson R (2006) Serious ocular complications of zoledronate. Clin Oncol R Coll Radiol 18:545–6PubMedCrossRef
9.
Kaur H, Uy C, Kelly J et al (2011) Orbital inflammatory disease in a patient treated with zoledronate. Endocr Pract 17:e101–3PubMedCrossRef
10.
Patel DV, Horne A, House M et al (2013) The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology 120:773–6PubMedCrossRef
11.
Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–16PubMedCrossRef
12.
Aurich-Barrera B, Wilton L, Harris S et al (2006) Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England. Drug Saf 29:151–60PubMedCrossRef
13.
French DD, Margo CE (2008) Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 28:889–93PubMedCrossRef
14.
15.
16.
Richards JC, Wiffen SJ (2006) Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. Cornea 25:1100–1PubMedCrossRef
17.
Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118:220–4PubMedCrossRef
18.
Fraunfelder FW, Fraunfelder FT (2003) Bisphosphonates and ocular inflammation. N Engl J Med 348:1187–8PubMedCrossRef
19.
Wakefield D, Gray P, Chang J et al (2010) The role of PAMPs and DAMPs in the pathogenesis of acute and recurrent anterior uveitis. Br J Ophthalmol 94:271–4PubMedCrossRef
20.
Roelofs AJ, Jauhiainen M, Monkkonen H et al (2009) Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144:245–50PubMedCentralPubMedCrossRef
21.
Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.​OpenEpi.​com, updated 2013/04/06. Accessed 13 Jan 2014
22.
Metadata
Title
Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial
Authors
D. V. Patel
M. Bolland
Z. Nisa
F. Al-Abuwsi
M. Singh
A. Horne
I. R. Reid
C. N. J. McGhee
Publication date
01-02-2015
Publisher
Springer London
Published in
Osteoporosis International / Issue 2/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2872-5

Other articles of this Issue 2/2015

Osteoporosis International 2/2015 Go to the issue

Original Article

Self-perceived facture risk: factors underlying women’s perception of risk for osteoporotic fractures: the Risk-Stratified Osteoporosis Strategy Evaluation study (ROSE)

Original Article

Incident type 2 diabetes and hip fracture risk: a population-based matched cohort study

Original Article

Low skeletal muscle mass associates with low femoral neck strength, especially in older Korean women: the Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV)

Original Article

Predictors of re-fracture amongst patients managed within a secondary fracture prevention program: a 7-year prospective study

Original Article

The interactions between municipal socioeconomic status and age on hip fracture risk

Original Article

Increased risk of cardiovascular events in end-stage renal disease patients with osteoporosis: a nationwide population-based cohort study